JP2022532271A5 - - Google Patents

Info

Publication number
JP2022532271A5
JP2022532271A5 JP2021534180A JP2021534180A JP2022532271A5 JP 2022532271 A5 JP2022532271 A5 JP 2022532271A5 JP 2021534180 A JP2021534180 A JP 2021534180A JP 2021534180 A JP2021534180 A JP 2021534180A JP 2022532271 A5 JP2022532271 A5 JP 2022532271A5
Authority
JP
Japan
Prior art keywords
peptide
antibody
seq
cell
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/086037 external-priority patent/WO2020127546A2/en
Publication of JP2022532271A publication Critical patent/JP2022532271A/ja
Publication of JP2022532271A5 publication Critical patent/JP2022532271A5/ja
Pending legal-status Critical Current

Links

JP2021534180A 2018-12-18 2019-12-18 がんに対するb*08拘束性ペプチドとペプチド組み合わせによる免疫療法および関連方法 Pending JP2022532271A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862781342P 2018-12-18 2018-12-18
US62/781,342 2018-12-18
DE102018132617 2018-12-18
DE102018132617.3 2018-12-18
US201962884507P 2019-08-08 2019-08-08
US62/884,507 2019-08-08
PCT/EP2019/086037 WO2020127546A2 (en) 2018-12-18 2019-12-18 Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods

Publications (2)

Publication Number Publication Date
JP2022532271A JP2022532271A (ja) 2022-07-14
JP2022532271A5 true JP2022532271A5 (https=) 2022-12-27

Family

ID=69104402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534180A Pending JP2022532271A (ja) 2018-12-18 2019-12-18 がんに対するb*08拘束性ペプチドとペプチド組み合わせによる免疫療法および関連方法

Country Status (19)

Country Link
US (4) US11779605B2 (https=)
EP (1) EP3897698A2 (https=)
JP (1) JP2022532271A (https=)
KR (1) KR20210104674A (https=)
CN (1) CN113260376A (https=)
AU (1) AU2019400780A1 (https=)
BR (1) BR112021010432A2 (https=)
CA (1) CA3108747A1 (https=)
CL (1) CL2021001336A1 (https=)
CO (1) CO2021003997A2 (https=)
CR (1) CR20210329A (https=)
IL (2) IL310379A (https=)
MA (1) MA54519A (https=)
MX (1) MX2021007313A (https=)
PE (1) PE20211772A1 (https=)
PH (1) PH12021551460A1 (https=)
SG (1) SG11202103498YA (https=)
TW (1) TW202039535A (https=)
WO (1) WO2020127546A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
WO2021188743A2 (en) * 2020-03-20 2021-09-23 Neo7Logix, Llc Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1194542A1 (en) 1999-03-02 2002-04-10 Ludwig Institute For Cancer Research Cloning of cdna of mage's 5,8,9 and 11 and their uses in diagnosis of cancer
EP1118860A1 (en) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1951891B1 (en) 2005-11-14 2012-02-15 Université Laval Cancer antigen mage-a9 and uses thereof
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
DE102013012432A1 (de) 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
WO2018189148A1 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法

Similar Documents

Publication Publication Date Title
JP2021168652A5 (https=)
JP2021514178A5 (https=)
JP2024041841A5 (https=)
JP2018529320A5 (https=)
JP2018511321A5 (https=)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019502360A5 (https=)
JP2018510628A5 (https=)
US12415833B2 (en) Method for activating helper T cell
JP2018520653A5 (https=)
JP2018518937A5 (https=)
JP2024099580A5 (https=)
JP2019510465A5 (https=)
JP2018509135A5 (https=)
JP2018536383A5 (https=)
JP2018518956A5 (https=)
JP2018519243A5 (https=)
JP2019511214A5 (https=)
JP2019506838A5 (https=)
JP2018521641A5 (https=)
JP2021535900A5 (https=)
JP2017525336A5 (https=)
JP2017502076A5 (https=)
JP2018530579A (ja) ウイルス性癌ネオエピトープのための組成物および方法
CN104995203B (zh) 辅助性t细胞的活化方法